a reply to: paleorchid13
What got our attention is the FDA said yesterday, that they have finally
told giant drug-maker Bayer Corp. NOT to expect the agency to give the
go-ahead for labels listing aspirin as a drug for primary prevention of heart attacks and other problems
Why not last year or the year before?
But a day before the announcement of the merger
True, no problem there
Like I said, maybe it's just me
Now with the merger, it was part of the deal that Merck will pay Bayer $1 billion upfront, plus potential additional milestone payments of
up to $1.2 billion if sales goals are reached
In the process, the 2 are going to be collaborating to co-develop and market certain prescription heart drugs, including Bayer's Adempas
And how are the sales goals going to be reached?
Cut down on OTC products such as apirin
And how to cut down on the sales of aspirin?
Get the FDA to back pedal on their benefits & denounce them, unsure of their results/saftey
So maybe there is nothing to see here
But I can't help but feel like there is a lot more at stake here than just 'Aspirin isn't safe for you'
The FDA has been shown in the past not to be trustworthy
They usually follow the almighty dollar until people start dying or have extremely severe side effects to the point where the lawsuits by the victim's
families just can't be ignored any more
Of course by then, the drug companies have made billions of dollars off the med so it won't matter if they have to pull the drug off the market
edit on 6-5-2014 by snarky412 because: (no reason given)